About Us

Clover was founded by a team of world-class scientists dedicated to a healthier future through the discovery, development, and delivery of breakthrough therapies for patients with the greatest unmet need. The founding leaders brought decades of experience and expertise in biologics development back to China, carrying out their belief that millions of Chinese patients and many more worldwide deserve access to modern biological medicines.

In past few years, Clover has grown from a 20-person team to a global R&D powerhouse with a diverse global team of approximately 450 members, a robust pipeline enabled by our proprietary Trimer-Tag© technology, large in-house manufacturing capabilities, and strong partnerships with internationally renowned healthcare organizations.

Timeline

2007
In 2007,Clover was founded as a research laboratory

2016
In Jul 2016,Clover executes agreement to establish and build 35,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, China and secures full-financing for the project (>RMB 350 million / >US$ 55 million)

2017
In Dec 2017,Clover completes Series A financing (RMB 62.8 million / US$ 9.5 million)

2018
In Jun 2018,First patient dosed with a product utilizing Trimer-Tag© technology (Phase 1 study of SCB-313 for treatment of cancer patients with malignant ascites)

2019
In Nov 2019,Clover completes Series B financing (RMB 304 million / US$ 43 million)

2020
In Jan 2020,Clover initiates development of COVID-19 vaccine candidate utilizing Trimer-Tag© technology

2020
In Feb-Mar 2020,Clover announces cross-border research collaborations with GSK and Dynavax utilizing their respective adjuvants for the development of COVID-19 vaccines

2020
In Apr 2020,Funding and collaboration with CEPI announced for Clover’s COVID-19 vaccine

2020
In Jun 2020,Clover completes Series B-2 financing (US$ 24 million / RMB 172 million) from Hillhouse Capital

2020
In Jun 2020,First participant dosed with Clover’s COVID-19 vaccine in Phase 1 clinical study

2020
In Jul 2020,CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate with an additional USD $66 million investment

2020
In Nov 2020,CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure (up to $328 million in grant funding)

2020
In Dec 2020,Clover announces positive Phase 1 data for its adjuvanted S-Trimer COVID-19 vaccine candidates

2021
In Feb 2021,Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing